Methemoglobinemia secondary to rasburicase in cancer: Non drug-related oxidative stress
To the Editor, Administration of rasburicase to prevent or mitigate tumor lysis syndrome in various types of cancer is implicated with the rare but potentially fatal adverse effect of methemoglobinemia, which is aggravated in genetically susceptible patients with G6PD deficiency. In this regard, I have read with great interest the paper published by Ng et al. 1 titled ''Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review,'' where the authors describe a patient with a highly aggressive Burkitt lymphoma who developed a rasburicase-induced methemoglobinemia. Although it is known that rasburicaseinduced peroxide hydrogen byproduct can bring about methemoglobin formation, there are some pitfalls that must be overcome and caveats to be considered since rasburicase may not be the sole culprit for the inception and pathogenesis of this condition, and other host factors and cancer/disease characteristics should be taken into account. For instance, tumor lysis syndrome can per se instigate a systemic inflammatory response syndrome due to the release of pro-inflammatory cytokines, which in turn leads to an increased liberation of free radicals and reactive oxygen species, and more importantly, nitric oxide production, all of them known factors that can elicit methemoglobinemia. 2 Cancer or neoplastic conditions are associated with the generation of reactive oxygen species and underproduction of antioxidant enzymes levels such as catalases, lactoperoxidases, glutathione peroxidases, and superoxide dismutases, as well as of small antioxidant molecules like ascorbic acid, methionine, or glutathione, and therefore contributing to the derangements of redox state and ultimately leading to an increased risk of methemoglobin generation. 3, 4 Adding to this intrinsic cancer-derived oxidative stress environment is the conjugation of a sudden decrease of serum uric acid levels, an important and potent free-radical scavenger, and the heightened enzymatic activity of xanthine oxidase, which generates reactive oxygen species. 5, 6 Another important remark is the fact that lower than conventional rasburicase dosages may provoke methemoglobinemia, hinting to other non drug-related etiologies acting in combination. 7 Taken these factors altogether, it seems that, due to the imbalances between high oxidative stress and low antioxidant protective mechanisms, cancer patients are intrinsically more prone and susceptible to the triggering of methemoglobin formation upon rasburicase administration independently of sex, ethnicity, or even G6PD status. Therefore, one can assume that instead of trying to screen all high-risk patients for G6PD, which is not cost-effective and logistically difficult, a more reasonable and less pricey approach could be the prophylactic administration of ascorbic acid to all cancer patients before cytotorreductive and rasburicase therapy, or in a pre-emptive fashion only to those showing initial laboratorial signs of tumor lysis syndrome to prevent methaemoglobin generation. 8 
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